Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics
Abstract We investigated the association between GSTM1 or GSTT1 polymorphisms and clinical outcomes in 133 younger patients with AML of intermediate-risk cytogenetics. Clinical outcomes were not significantly different among the GSTM1 polymorphism genotypes, whereas cumulative incidence of relapse (...
Gespeichert in:
| Veröffentlicht in: | Leukemia research 2009-03, Vol.33 (3), p.426-433 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 433 |
|---|---|
| container_issue | 3 |
| container_start_page | 426 |
| container_title | Leukemia research |
| container_volume | 33 |
| creator | Lee, Ho Sup Lee, Je-Hwan Hur, Eun-Hye Lee, Michael Jinpyo Lee, Jung-Hee Kim, Dae-Young Kim, Se Hyung Seol, Miee Kang, Sol-Ip Ryu, Seong-Gil Kang, Young-Ah Lee, Young-Shin Kang, Mun Jung Seo, Eul-Ju Kim, Yang Soo Chi, Hyun Sook Park, Chan Jeoung Jang, Seongsoo Yun, Sung-Cheol Lee, Kyoo-Hyung |
| description | Abstract We investigated the association between GSTM1 or GSTT1 polymorphisms and clinical outcomes in 133 younger patients with AML of intermediate-risk cytogenetics. Clinical outcomes were not significantly different among the GSTM1 polymorphism genotypes, whereas cumulative incidence of relapse (CIR) was significantly lower and event-free survival (EFS) was significantly higher in patients with the GSTT1 -present genotype compared with those with the GSTT1 -null genotype (CIR at 5 year, 28.9% vs. 44.6%, P = 0.018; EFS at 5 year, 51.4% vs. 34.1%, P = 0.029). Our results suggest that GSTT1 gene polymorphism has significant clinical implications in younger patients with AML of intermediate-risk cytogenetics. |
| doi_str_mv | 10.1016/j.leukres.2008.07.021 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66859653</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0145212608003494</els_id><sourcerecordid>66859653</sourcerecordid><originalsourceid>FETCH-LOGICAL-c449t-7a2a569621817253504e46cc9f99628f914e76056a775ade0e94d3cf198467833</originalsourceid><addsrcrecordid>eNqFksGOFCEQhonRuOPoI2g4eesRmoaGi8ZMdNdkjYcdzwTp6llmumEEejf9Bj62dGYSEy97okL--gv-rxB6S8mGEio-HDYDTMcIaVMTIjek3ZCaPkMrKltWccn4c7QitOFVTWtxhV6ldCCEcEXVS3RVRIJI1q7Qn-3gvLNmwMntvetL6S3g0OPru913io3vlmpH8SkM8xji6d6lMWHn8Rwmv4eITyY78DnhR5fvsbFTBjzOMATX4eWNMDqzGDqfIY7QOZOhii4dsZ1z2IOH7Gx6jV70Zkjw5nKu0c-vX3bbm-r2x_W37efbyjaNylVrasOFEjWVtK0546SBRlirelUuZa9oA-VvXJi25aYDAqrpmO2pko1oJWNr9P7se4rh9wQp69ElC8NgPIQpaSEkV4I_LawJk5yVFNeIn4U2hpQi9PoU3WjirCnRCyt90BdWemGlSasLq9L37jJg-lVi-dd1gVMEn84CKHk8OIg62ZK0LRFGsFl3wT054uN_DvaC-wgzpEOYoi9ha6pTrYm-WxZm2RciCWGNathf6ny96g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20385308</pqid></control><display><type>article</type><title>Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Lee, Ho Sup ; Lee, Je-Hwan ; Hur, Eun-Hye ; Lee, Michael Jinpyo ; Lee, Jung-Hee ; Kim, Dae-Young ; Kim, Se Hyung ; Seol, Miee ; Kang, Sol-Ip ; Ryu, Seong-Gil ; Kang, Young-Ah ; Lee, Young-Shin ; Kang, Mun Jung ; Seo, Eul-Ju ; Kim, Yang Soo ; Chi, Hyun Sook ; Park, Chan Jeoung ; Jang, Seongsoo ; Yun, Sung-Cheol ; Lee, Kyoo-Hyung</creator><creatorcontrib>Lee, Ho Sup ; Lee, Je-Hwan ; Hur, Eun-Hye ; Lee, Michael Jinpyo ; Lee, Jung-Hee ; Kim, Dae-Young ; Kim, Se Hyung ; Seol, Miee ; Kang, Sol-Ip ; Ryu, Seong-Gil ; Kang, Young-Ah ; Lee, Young-Shin ; Kang, Mun Jung ; Seo, Eul-Ju ; Kim, Yang Soo ; Chi, Hyun Sook ; Park, Chan Jeoung ; Jang, Seongsoo ; Yun, Sung-Cheol ; Lee, Kyoo-Hyung</creatorcontrib><description>Abstract We investigated the association between GSTM1 or GSTT1 polymorphisms and clinical outcomes in 133 younger patients with AML of intermediate-risk cytogenetics. Clinical outcomes were not significantly different among the GSTM1 polymorphism genotypes, whereas cumulative incidence of relapse (CIR) was significantly lower and event-free survival (EFS) was significantly higher in patients with the GSTT1 -present genotype compared with those with the GSTT1 -null genotype (CIR at 5 year, 28.9% vs. 44.6%, P = 0.018; EFS at 5 year, 51.4% vs. 34.1%, P = 0.029). Our results suggest that GSTT1 gene polymorphism has significant clinical implications in younger patients with AML of intermediate-risk cytogenetics.</description><identifier>ISSN: 0145-2126</identifier><identifier>EISSN: 1873-5835</identifier><identifier>DOI: 10.1016/j.leukres.2008.07.021</identifier><identifier>PMID: 18760837</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Age Factors ; AML ; Cytogenetic Analysis ; Disease-Free Survival ; Female ; Glutathione Transferase - genetics ; GST polymorphisms ; Hematology, Oncology and Palliative Medicine ; Humans ; Intermediate-risk cytogenetics ; Leukemia, Myeloid, Acute - genetics ; Male ; Middle Aged ; Polymorphism, Genetic ; Prognosis ; Recurrence ; Risk Factors ; Treatment Outcome ; Young Adult</subject><ispartof>Leukemia research, 2009-03, Vol.33 (3), p.426-433</ispartof><rights>Elsevier Ltd</rights><rights>2008 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c449t-7a2a569621817253504e46cc9f99628f914e76056a775ade0e94d3cf198467833</citedby><cites>FETCH-LOGICAL-c449t-7a2a569621817253504e46cc9f99628f914e76056a775ade0e94d3cf198467833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.leukres.2008.07.021$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18760837$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Ho Sup</creatorcontrib><creatorcontrib>Lee, Je-Hwan</creatorcontrib><creatorcontrib>Hur, Eun-Hye</creatorcontrib><creatorcontrib>Lee, Michael Jinpyo</creatorcontrib><creatorcontrib>Lee, Jung-Hee</creatorcontrib><creatorcontrib>Kim, Dae-Young</creatorcontrib><creatorcontrib>Kim, Se Hyung</creatorcontrib><creatorcontrib>Seol, Miee</creatorcontrib><creatorcontrib>Kang, Sol-Ip</creatorcontrib><creatorcontrib>Ryu, Seong-Gil</creatorcontrib><creatorcontrib>Kang, Young-Ah</creatorcontrib><creatorcontrib>Lee, Young-Shin</creatorcontrib><creatorcontrib>Kang, Mun Jung</creatorcontrib><creatorcontrib>Seo, Eul-Ju</creatorcontrib><creatorcontrib>Kim, Yang Soo</creatorcontrib><creatorcontrib>Chi, Hyun Sook</creatorcontrib><creatorcontrib>Park, Chan Jeoung</creatorcontrib><creatorcontrib>Jang, Seongsoo</creatorcontrib><creatorcontrib>Yun, Sung-Cheol</creatorcontrib><creatorcontrib>Lee, Kyoo-Hyung</creatorcontrib><title>Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics</title><title>Leukemia research</title><addtitle>Leuk Res</addtitle><description>Abstract We investigated the association between GSTM1 or GSTT1 polymorphisms and clinical outcomes in 133 younger patients with AML of intermediate-risk cytogenetics. Clinical outcomes were not significantly different among the GSTM1 polymorphism genotypes, whereas cumulative incidence of relapse (CIR) was significantly lower and event-free survival (EFS) was significantly higher in patients with the GSTT1 -present genotype compared with those with the GSTT1 -null genotype (CIR at 5 year, 28.9% vs. 44.6%, P = 0.018; EFS at 5 year, 51.4% vs. 34.1%, P = 0.029). Our results suggest that GSTT1 gene polymorphism has significant clinical implications in younger patients with AML of intermediate-risk cytogenetics.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>AML</subject><subject>Cytogenetic Analysis</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Glutathione Transferase - genetics</subject><subject>GST polymorphisms</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Intermediate-risk cytogenetics</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Polymorphism, Genetic</subject><subject>Prognosis</subject><subject>Recurrence</subject><subject>Risk Factors</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0145-2126</issn><issn>1873-5835</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFksGOFCEQhonRuOPoI2g4eesRmoaGi8ZMdNdkjYcdzwTp6llmumEEejf9Bj62dGYSEy97okL--gv-rxB6S8mGEio-HDYDTMcIaVMTIjek3ZCaPkMrKltWccn4c7QitOFVTWtxhV6ldCCEcEXVS3RVRIJI1q7Qn-3gvLNmwMntvetL6S3g0OPru913io3vlmpH8SkM8xji6d6lMWHn8Rwmv4eITyY78DnhR5fvsbFTBjzOMATX4eWNMDqzGDqfIY7QOZOhii4dsZ1z2IOH7Gx6jV70Zkjw5nKu0c-vX3bbm-r2x_W37efbyjaNylVrasOFEjWVtK0546SBRlirelUuZa9oA-VvXJi25aYDAqrpmO2pko1oJWNr9P7se4rh9wQp69ElC8NgPIQpaSEkV4I_LawJk5yVFNeIn4U2hpQi9PoU3WjirCnRCyt90BdWemGlSasLq9L37jJg-lVi-dd1gVMEn84CKHk8OIg62ZK0LRFGsFl3wT054uN_DvaC-wgzpEOYoi9ha6pTrYm-WxZm2RciCWGNathf6ny96g</recordid><startdate>20090301</startdate><enddate>20090301</enddate><creator>Lee, Ho Sup</creator><creator>Lee, Je-Hwan</creator><creator>Hur, Eun-Hye</creator><creator>Lee, Michael Jinpyo</creator><creator>Lee, Jung-Hee</creator><creator>Kim, Dae-Young</creator><creator>Kim, Se Hyung</creator><creator>Seol, Miee</creator><creator>Kang, Sol-Ip</creator><creator>Ryu, Seong-Gil</creator><creator>Kang, Young-Ah</creator><creator>Lee, Young-Shin</creator><creator>Kang, Mun Jung</creator><creator>Seo, Eul-Ju</creator><creator>Kim, Yang Soo</creator><creator>Chi, Hyun Sook</creator><creator>Park, Chan Jeoung</creator><creator>Jang, Seongsoo</creator><creator>Yun, Sung-Cheol</creator><creator>Lee, Kyoo-Hyung</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20090301</creationdate><title>Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics</title><author>Lee, Ho Sup ; Lee, Je-Hwan ; Hur, Eun-Hye ; Lee, Michael Jinpyo ; Lee, Jung-Hee ; Kim, Dae-Young ; Kim, Se Hyung ; Seol, Miee ; Kang, Sol-Ip ; Ryu, Seong-Gil ; Kang, Young-Ah ; Lee, Young-Shin ; Kang, Mun Jung ; Seo, Eul-Ju ; Kim, Yang Soo ; Chi, Hyun Sook ; Park, Chan Jeoung ; Jang, Seongsoo ; Yun, Sung-Cheol ; Lee, Kyoo-Hyung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c449t-7a2a569621817253504e46cc9f99628f914e76056a775ade0e94d3cf198467833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>AML</topic><topic>Cytogenetic Analysis</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Glutathione Transferase - genetics</topic><topic>GST polymorphisms</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Intermediate-risk cytogenetics</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Polymorphism, Genetic</topic><topic>Prognosis</topic><topic>Recurrence</topic><topic>Risk Factors</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Ho Sup</creatorcontrib><creatorcontrib>Lee, Je-Hwan</creatorcontrib><creatorcontrib>Hur, Eun-Hye</creatorcontrib><creatorcontrib>Lee, Michael Jinpyo</creatorcontrib><creatorcontrib>Lee, Jung-Hee</creatorcontrib><creatorcontrib>Kim, Dae-Young</creatorcontrib><creatorcontrib>Kim, Se Hyung</creatorcontrib><creatorcontrib>Seol, Miee</creatorcontrib><creatorcontrib>Kang, Sol-Ip</creatorcontrib><creatorcontrib>Ryu, Seong-Gil</creatorcontrib><creatorcontrib>Kang, Young-Ah</creatorcontrib><creatorcontrib>Lee, Young-Shin</creatorcontrib><creatorcontrib>Kang, Mun Jung</creatorcontrib><creatorcontrib>Seo, Eul-Ju</creatorcontrib><creatorcontrib>Kim, Yang Soo</creatorcontrib><creatorcontrib>Chi, Hyun Sook</creatorcontrib><creatorcontrib>Park, Chan Jeoung</creatorcontrib><creatorcontrib>Jang, Seongsoo</creatorcontrib><creatorcontrib>Yun, Sung-Cheol</creatorcontrib><creatorcontrib>Lee, Kyoo-Hyung</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Ho Sup</au><au>Lee, Je-Hwan</au><au>Hur, Eun-Hye</au><au>Lee, Michael Jinpyo</au><au>Lee, Jung-Hee</au><au>Kim, Dae-Young</au><au>Kim, Se Hyung</au><au>Seol, Miee</au><au>Kang, Sol-Ip</au><au>Ryu, Seong-Gil</au><au>Kang, Young-Ah</au><au>Lee, Young-Shin</au><au>Kang, Mun Jung</au><au>Seo, Eul-Ju</au><au>Kim, Yang Soo</au><au>Chi, Hyun Sook</au><au>Park, Chan Jeoung</au><au>Jang, Seongsoo</au><au>Yun, Sung-Cheol</au><au>Lee, Kyoo-Hyung</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics</atitle><jtitle>Leukemia research</jtitle><addtitle>Leuk Res</addtitle><date>2009-03-01</date><risdate>2009</risdate><volume>33</volume><issue>3</issue><spage>426</spage><epage>433</epage><pages>426-433</pages><issn>0145-2126</issn><eissn>1873-5835</eissn><abstract>Abstract We investigated the association between GSTM1 or GSTT1 polymorphisms and clinical outcomes in 133 younger patients with AML of intermediate-risk cytogenetics. Clinical outcomes were not significantly different among the GSTM1 polymorphism genotypes, whereas cumulative incidence of relapse (CIR) was significantly lower and event-free survival (EFS) was significantly higher in patients with the GSTT1 -present genotype compared with those with the GSTT1 -null genotype (CIR at 5 year, 28.9% vs. 44.6%, P = 0.018; EFS at 5 year, 51.4% vs. 34.1%, P = 0.029). Our results suggest that GSTT1 gene polymorphism has significant clinical implications in younger patients with AML of intermediate-risk cytogenetics.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>18760837</pmid><doi>10.1016/j.leukres.2008.07.021</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0145-2126 |
| ispartof | Leukemia research, 2009-03, Vol.33 (3), p.426-433 |
| issn | 0145-2126 1873-5835 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66859653 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adolescent Adult Age Factors AML Cytogenetic Analysis Disease-Free Survival Female Glutathione Transferase - genetics GST polymorphisms Hematology, Oncology and Palliative Medicine Humans Intermediate-risk cytogenetics Leukemia, Myeloid, Acute - genetics Male Middle Aged Polymorphism, Genetic Prognosis Recurrence Risk Factors Treatment Outcome Young Adult |
| title | Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T07%3A10%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20significance%20of%20GSTM1%20and%20GSTT1%20polymorphisms%20in%20younger%20patients%20with%20acute%20myeloid%20leukemia%20of%20intermediate-risk%20cytogenetics&rft.jtitle=Leukemia%20research&rft.au=Lee,%20Ho%20Sup&rft.date=2009-03-01&rft.volume=33&rft.issue=3&rft.spage=426&rft.epage=433&rft.pages=426-433&rft.issn=0145-2126&rft.eissn=1873-5835&rft_id=info:doi/10.1016/j.leukres.2008.07.021&rft_dat=%3Cproquest_cross%3E66859653%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20385308&rft_id=info:pmid/18760837&rft_els_id=1_s2_0_S0145212608003494&rfr_iscdi=true |